The main purpose of this phase II trial is to evaluate the clinical feasibility-in terms of
patients without dose limiting toxicities or premature treatment withdrawal or death-of
administering adjuvant chemotherapy of pemetrexed followed by pemetrexed/oxaliplatin
immediately post-video-assisted thoracic surgery (VATS) in patients with completely resected
Non-Small Cell Lung Cancer (NSCLC).